ZSPC Releases 2025 Annual Report: Innovation-Driven Transformation Delivers Strong Results

Source: Shanghai Securities News·China Securities Network

China Securities News, Shanghai Stock Exchange News, April 28, 2026, eveningZhongsheng PharmaceuticalDisclosure of the 2025 Annual Report and the First Quarter Report of 2026. The reports show that the company's core operating indicators have improved across the board, the results of innovative transformation have been effectively implemented, demonstrating strong development resilience and growth potential in the opening year of the "Fifteenth Five-Year Plan."

In 2025, Zhongsheng Pharmaceutical achieved operating revenue of 2.523 billion yuan, a year-on-year increase of 2.24%; net profit attributable to shareholders of 276 million yuan, a year-on-year increase of 192.18%; non-recurring net profit of 281 million yuan, a year-on-year increase of 207.97%. Core profitability indicators achieved substantial breakthroughs, successfully reaching the annual target of turning losses into profits. The improvement in performance was driven by the dissipation of asset impairment provisions, recovery in core business segments, optimization of product mix, and strict control of costs and expenses.

The 2026 Q1 report further confirms the certainty of a performance recovery: net profit attributable to shareholders was approximately 99.83 million yuan in Q1, a year-on-year increase of 20.83%; non-recurring net profit was 103 million yuan, a year-on-year increase of 30.90%; net cash flow from operating activities was 142 million yuan, a year-on-year increase of 594.62%. The continuously positive trend lays a solid foundation for profitability throughout the year.

In 2025, the company's innovative Class I influenza drug, Angladivir Tablets, was successfully approved for marketing. This drug is the world's first First-In-Class small molecule innovative drug targeting the PB2 subunit of the influenza virus RNA polymerase. It offers advantages such as faster symptom relief, shorter fever reduction time, and lower drug resistance risk, and has been granted PCT patents in multiple countries including China and the United States. In December last year, Angladivir was successfully included in the medical insurance system, greatly improving the product’s accessibility, and is expected to become a core growth driver for the company's long-term development.

Guangdong Zhongsheng Pharmaceutical Co., Ltd. Completes Enrollment for Three Phase III Clinical Trials of RAY1225 InjectionThe three Phase III clinical trials of the investigational product RAY1225 injection have completed enrollment of all participants. The drug exhibits dual receptor agonist activity for GLP-1 and GIP, with the potential for an ultra-long-acting dosing regimen of once every two weeks. It focuses on two highly prevalent disease areas: obesity/overweight and type 2 diabetes. Additionally, the product has received approval to initiate new clinical trials for "metabolic dysfunction-associated steatohepatitis (MASH)" and "obesity with obstructive sleep apnea." Zhongsheng Pharmaceutical has granted Qilu Pharmaceutical the commercial rights for RAY1225 in China, while retaining intellectual property rights and all overseas rights for the product. The collaboration includes an upfront payment of 200 million yuan and milestone payments totaling 800 million yuan. After commercialization, Zhongsheng Pharmaceutical will also receive double-digit royalties based on net sales. The drug’s indications for weight loss and glycemic control are expected to be submitted for marketing authorization progressively between 2026 and 2027, becoming another core asset in the company's innovative pipeline.

Zhongsheng Pharmaceutical adheres to the strategic positioning of "Traditional Chinese Medicine as the foundation, innovation-led, quality and efficiency combined," achieving a key transition from "strengthening the foundation with traditional medicine" to "breaking new ground with innovative drugs" by 2025. In the future, the company will continue to increase R&D investment, promote the transformation of innovative achievements, provide better health protection for patients, and create greater value for investors. (Hua Huimin)